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The immune System is a natural 
Target for estrogen Action: Opposing 
effects of estrogen in Two 
Prototypical Autoimmune Diseases
Deena Khan and S. Ansar Ahmed*
 Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, 
Blacksburg, VA, USA
Analogous to other physiological systems, the immune system also demonstrates 
remarkable sex differences. Although the reasons for sex differences in immune 
responses are not precisely understood, it potentially involves differences in sex hor-
mones (estrogens, androgens, and differential sex hormone receptor-mediated events), 
X-chromosomes, microbiome, epigenetics among others. Overall, females tend to have 
more responsive and robust immune system compared to their male counterparts. 
It is therefore not surprising that females respond more aggressively to self-antigens 
and are more susceptible to autoimmune diseases. Female hormone (estrogen or 
17β-estradiol) can potentially act on all cellular subsets of the immune system through 
estrogen receptor-dependent and -independent mechanisms. This minireview highlights 
differential expression of estrogen receptors on immune cells, major estrogen-mediated 
signaling pathways, and their effect on immune cells. Since estrogen has varied effects 
in female-predominant autoimmune diseases such as multiple sclerosis and systemic 
lupus erythematosus, we will mechanistically postulate the potential differential role of 
estrogen in these chronic debilitating diseases.
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inTRODUCTiOn
Although the principal function of sex steroid action is to regulate reproductive functions, studies in 
diverse fields have unequivocally established that sex steroids also act on diverse non-reproductive 
tissues include immune, central nervous, cardiovascular, and skeletal systems, as well as cells from 
liver, skin, and kidneys (1–5). In this brief review, we will discuss estrogen effects on the immune 
cells, the estrogen-specific receptor expression on cells of the immune system, and key estrogen-
receptor mediated-signaling pathways involved. In addition, we will analyze the differential response 
of estrogen in two typical female-predominant autoimmune diseases.
TABLe 1 | List of key selected genes that are regulated by estrogen in 
cells of innate and adaptive immune system.
immune cell List of genes Reference
Neutrophil CINC-1, CINC-2β, CINC-3, TNFα, IL-6, IL-1β (8–10)
Macrophage iNOS, NO, IL-6, TNFα (12–16)
Dendritic 
cells
IL-6, IL-10, CXCL8, CCL2, TGFβ, IL-23, IL-12 (17, 18, 22)
Th1 IFNγ (23–25)
Th2 IL-4 (26)
Tregs FoxP3, PD-1, CTLA-4 (27–30)
B cells Immunoglobulin, CD22, SHP-1, Bcl-2, 
VCAM-1
(31)
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eSTROGen ReGULATiOn OF CeLLS OF 
THe innATe AnD ADAPTive iMMUne 
SYSTeM
There is now an enormous amount of literature on estrogen’s 
effects on the cells of the innate immune system [neutrophils, 
macrophages/monocytes, natural killer cells, dendritic cells 
(DC)], and the adaptive immune system (T and B cells). 
These aspects have been comprehensively covered in many 
reviews (5–7) and hence are beyond the scope of this minireview. 
Estrogens have been shown to regulate neutrophil numbers and 
functions that include chemotaxis, infiltration, production of 
superoxide anion and myeloperoxidase, induction of chemokines 
(cytokine induced neutrophil chemoattractants such as CINC-1, 
CINC-2β, and CINC-3, monocyte chemoattractant protein-1), 
and cytokines (e.g., TNF-α, IL-6, IL-1β) (8–10). Table 1 shows key 
selected genes that estrogen regulates in the cells of the immune 
system. Our laboratory has recently shown that in vivo estrogen-
treated C57BL/6 mice have increased splenic neutrophils com-
parable to that noticed in female autoimmune-prone MRL/lpr or 
C57BL/6-lpr (11). Estrogens can also alter macrophage function 
by regulating chemotaxis, phagocytic activity, and induction of 
cytokines, iNOS, and nitric oxide (12–16). Estrogen can also 
enhance differentiation of immature DCs into mature functional 
DCs, and regulate the expression of cytokines and chemokines 
such as IL-6, IL-10, CXCL8, and CCL2 (17, 18). Overall, mul-
tiple studies have demonstrated that estrogens can affect innate 
immune cell signaling (19–21).
Estrogen has been shown to modulate all subsets of T cells that 
include CD4+ (Th1, Th2, Th17, and Tregs) and CD8+ cells (32–35). 
Extensive studies have demonstrated that estrogen modulates 
IFNγ-secreting Th1 cells by enhancing IFNγ expression in both 
human and mice (23–25), which are potentially mediated by 
direct interaction of ER with Estrogen-response element (ERE) 
in the promoter region of the Ifnγ gene (24) and/or up-regulating 
Th-1-specific transcription factor T-bet (25, 36). ERα-deficient 
mice have decreased IFNγ+-secreting cells in lymph nodes, sug-
gesting estrogen-driven Th1 cell responsiveness is dependent on 
ERα-mediated signaling (37). Estrogen’s effect on Th2 cells and its 
prototypic cytokine, IL-4 is less marked, either having no effect 
(25, 38, 39) or stimulatory effect of estrogen on IL-4 secretion and 
GATA-3 expression (26) or a positive correlation between men-
strual estrogen cycle levels and IL-4 (40). Interestingly, high levels 
of estrogen (e.g., pregnancy level) are known to skew the immune 
response from Th1 (IFNγ) to Th2 (IL-4) (41–43). The effects of 
estrogen on Th17 subset have also been recently reported, albeit 
with varied response to estrogen depending on the experimental 
conditions. In periodontal ligament cells culture, addition of 
estrogen enhances IL-1β-mediated IL-17F production (44). In 
adult cystic fibrosis male mice, estrogen increases the severity of 
pneumonia, in part by increased Th17-regulated inflammation 
(45). However, it has also been shown that estrogen deficiency 
in postmenopausal women is associated with increased IL-17A 
levels (46). Estrogen also promotes the expansion and frequency 
of Treg cells, which play a critical role in downregulating 
immune responses (28, 30) and upregulating the expression of 
FoxP3, PD-1, and CTLA-4 via ERα-mediated signaling (27–30). 
Protective effects of estrogen in autoimmune conditions such 
as MS and RA are believed to be due to a combined result of 
estrogen-mediated Treg expansion and activation (27, 47, 48).
Estrogen can also have profound effects on B cell differentiation, 
activity, function (49, 50), and survival by increasing expression 
of genes such as cd22, shp-1, bcl-2, and vcam-1 (31) Estrogen has 
been shown to increase plasma cell and autoantibody producing 
cells numbers (49, 51). Although signaling by either ERα or β 
has shown to alter B cell maturation, ERα engagement has been 
shown to be critical for autoimmunity (52).
The outcome of response of estrogen on the immune system 
can vary depending upon the level of estrogens, cell type, acti-
vation state of cells, local environment, and the experimental 
context. In many of these studies, it is unclear if estrogenic effects 
are mediated through ER-dependent or -independent pathways. 
Nonetheless, the estrogen-mediated effects are apparent in all 
major innate and adaptive immune cells.
eSTROGen ReCePTOR eXPReSSiOn in 
THe CeLLS OF THe iMMUne SYSTeM
Estrogen-mediated signaling is a result of fine-tuned balance 
between two distinct receptors ERα (NR3A1) and ERβ (NR3A2) 
that are encoded by ESR-1 and ESR-2 genes expressed on human 
chromosomes 6 and 14, respectively (53). These receptors act 
as ligand-activated transcription factors and, therefore, directly 
regulate a broad range of estrogen-responsive genes. The bio-
chemical similarities and differences between ERα and ERβ are 
depicted in Figure 1A. Eventhough both ERs have comparable 
affinity to estrogen and recognize the same ERE, they may have 
distinct, non-overlapping or even antagonist effects. There are 
different parameters that determine the overall effect of estrogen 
receptor-mediated signaling. These factors include: (i) differential 
distribution and expression of ERs in various cells and tissues, (ii) 
homo or hetero dimerization of the receptor, (iii) distinct splice 
variant ER isoforms, (iv) diverse signaling pathways triggered, (v) 
interaction with specific co-activators/-repressors, (vi) transacti-
vation, (vii) physiological or pathological states, and (viii) local 
tissue milieu, among others.
In most cells of the immune system ERα is expressed, which 
includes hematopoietic cells, bone marrow, thymus stromal 
cells and thymocytes (6, 7, 56–59), and murine splenic DC and 
FiGURe 1 | Structural description and percent sequence homology of human eRα and eRβ and schematic representation of estrogen receptor 
ligand-dependent and ligand-independent signaling. (A) shows comparison of human estrogen receptor α (595 aa) and a shorter estrogen receptor β (530 aa). 
These receptors are evolutionarily conserved and have five distinct structural and functional domains: DNA-binding domain (DBD; C domain), hinge domain (D), 
ligand-binding domain (LBD; E/F domain), and two transcriptional activation function domains AF-1 (in A/B domain) and AF-2 (in F domain). The binding of ligand 
(estrogens) to E domain results in conformational changes in the receptor (homo/hetero dimerization). The receptor dimer than translocates inside nuclei with the 
help of D domain. This domain is also important for post-translational modifications of receptor by acetylation, lipophilic moieties, and ubiquitination. The C domain 
then recognizes and binds to estrogen-response element (ERE) in DNA. AF-2 region interacts with co-regulatory proteins in ligand-dependent pathway. However, 
AF-1 region is activated in ligand-independent manner (54). (B) ER-mediated signaling occurs in a ligand-dependent (green arrows) and ligand-independent (red 
arrows). The ligand-dependent pathway is triggered by binding of either endogenous hormone or a synthetic compound to the ligand-binding domain of ERs in the 
cytosol. Different ligands induce unique conformational changes of ERs, and receptor dimerization (homodimers: ERα:ERα or ERβ:ERβ or heterodimer: ERα:ERβ), 
which then translocate into nuclei and bind to specific EREs (consisting of a 5-bp palindrome with a 3-bp spacer; GGTCAnnnTGACC) in the regulatory regions of 
estrogen responsive genes. This is also called “classical” signaling pathway. In “tethered” signaling pathway, ligand-activated ERs interact with other transcription 
factor complexes and bind to non-EREs by attaching to other transcription factors and not with ERE directly. In third ligand-dependent “non-genomic” pathway, 
ligand interacts with plasma membrane-bound ERs via palmitoylation on cysteine447, which results in activation of cytoplasmic signaling pathways, such as protein 
kinase C (PKC). In ligand-independent signaling pathway, there is phosphorylation/activation of ERs by other active signaling cascades in a cell (55). This activation 
results in both direct ERE and non-ERE dependent genomic actions. Abbreviation: Akt, protein kinase B; AP-1, activator protein 1; ERE, estrogen-response 
element; ER, estrogen receptor; ERK, extracellular signal-regulated kinase; FoxP3, fork box 3; GRP30, an orphan G-protein coupled receptor 30; iNOS, inducible 
nitric oxide synthase; PI3K, phosphatidylinositol-4, 5-bisphosphate 3-kinase; P, indicates phosphorylation.
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peritoneal macrophages (60). Whereas ERβ has a more restricted 
cellular expression and is preferentially expressed in thymus and 
spleen of human mid-gestational fetus (61), lymphocytes in human 
lymph nodes, rat thymocyte and stromal cells (58), murine bone 
marrow, and thymus (62, 63). Among T lymphocytes, CD4+ cells 
have more ERα levels compared to ERβ whereas CD8+ cells have 
low expression of both receptors. B cells, unlike CD4 cells, have 
more ERβ than ERα (64). Effect of ERα on the immune system 
is generally considered to be developmentally more prominent 
than ERβ (37) since ERα-deficient mice exhibit hypoplastic 
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thymus and spleen (65, 66), increased immature double-positive 
thymocytes (CD4+CD8+) and decreased CD4+CD8− cells. The 
balance between ERα and ERβ to maintain a physiological state 
is underlined by the observations that mice lacking ERα have 
increased immune complex-mediated glomerulonephritis, pro-
teinuria, infiltration of B cells in kidney, damage of tubular cells, 
and presence of serum anti-DNA antibodies (66, 67). The natural 
varied expression of ERs in different tissues and cell types, and 
during maturity, finely balances the overall outcome of estrogen-
mediated immune responses.
eSTROGen ReCePTOR-MeDiATeD CeLL 
SiGnALinG
In large part, estrogen mediates its effects by binding to specific 
estrogen receptors and triggering distinct signaling pathways to 
regulate a broad range of estrogen responsive genes. ER-mediated 
signaling can be broadly classified as either ligand dependent or 
ligand independent (Figure 1B). Additionally, post-translational 
modifications of ERs also affect ER signaling and biological func-
tions. These include: phosphorylation stimulates signaling; gly-
cosylation is important for ER localization; acetylation enhances 
ER-DNA binding activity, hormone sensitivity, and transcrip-
tional activity; sumoylation favors ERα-dependent transcrip-
tion; nitrosylation reduces DNA binding ability; ubiquitination 
promotes degradation; myristoylation and palmitoylation affect 
cross-talk of ERs with membrane proteins, trafficking, as well 
as signal transduction (68). It is thus not surprising that varied 
ER-mediated effects in different experimental and clinical situ-
ations may in part be due to local differential post-translational 
modifications of ER.
eSTROGen AnD AUTOiMMUne 
DiSeASeS
The pathogenesis of autoimmune diseases remains unclear despite 
extensive research over a few decades. However, multiple factors 
that regulate autoimmune diseases have been identified. These 
include: genetics; epigenetics (miRNA, methylation, and histone 
deacetylation); infections; and external and internal environmen-
tal triggers including hormones and microbiome. A majority of 
autoimmune diseases occur predominantly in women, a feature 
also noted in many animal models of autoimmune diseases (5, 
69). Initially, it was presumed that the sex bias is related to dif-
ferences in sex steroids, but it is now evident that several other 
factors contribute to the sex bias of autoimmune diseases that 
include X chromosomal abnormalities, X-chromosomal inacti-
vation, and fetal microchimerism. The effects of sex hormones 
(such as estrogens) on autoimmune diseases cannot be general-
ized and is context/disease-dependent. It is not surprising that 
the outcome of estrogen-mediated autoimmune responses is 
different among autoimmune diseases since estrogens affect all 
cells of the immune system, and the triggering and pathogenic 
mechanisms are varied among different diseases. This aspect of 
differential estrogen-mediated effects in autoimmune diseases, 
in two classical female-predominant diseases: an organ-specific 
[multiple sclerosis (MS)] and a non-organ-specific autoimmune 
disease (SLE), are highlighted below.
estrogen and MS
Multiple sclerosis (MS) and its experimental model (EAE) are 
characterized by the presence of myelin antigens reactive CD4+ 
T cells in the CNS, demyelination of axons resulting in axonal 
death, and altered CNS function. The women to men ratio for 
disease prevalence ranges from 2.3 to 3.5:1 (70). The exact mecha-
nism of this female predisposition of MS remains unknown. Yet 
intriguingly, the female sex hormone estrogen is protective in MS. 
Estrogens have been shown to have anti-inflammatory and neu-
roprotective effect in MS and EAE. Estrogen through principally 
ERα-dependent mechanism decreases autoantigen-specific pro-
inflammatory biomolecules (such as IFNγ, TNFα, IL-17, iNOS, 
and MCP-1), and inhibits inflammation and demyelination 
(32, 47, 48, 71). ERβ agonist diarylpropionitrile (DPN) protects 
oligodendrocytes by increasing endogenous myelination (72). A 
recent report has demonstrated that estrogen protects gray mat-
ter atrophy in EAE (73). In addition in the EAE model, estrogen 
inhibits CD4+ T cells expansion, increases proportions of Tregs 
and CD4+CD8− suppressor T cells (74), increases T cell apoptosis 
(75), and markedly alters expression pattern of 315 genes in spinal 
cord tissue of mice protected from EAE (76). In pregnant EAE 
mice, there is reduced CNS pathology and decreased TNFα and 
IL-17 production when compared to non-pregnant controls (77). 
The rate of relapse in females increases postpartum at a phase 
when there is a marked decrease in estrogen levels when compared 
to pregnancy levels (78, 79). In vivo estriol treatment promotes 
generation of tolerogenic DCs with increased activation markers 
(CD80 and CD86), inhibitory costimulatory markers (PD-L1, 
PD-L2, B7-H3, and B7-H4), and increased anti-inflammatory 
(IL-10 and TGFβ) and decreased pro-inflammatory (IL-12, 
IL-23, and IL-6) cytokine mRNA expression (22).
estrogen and SLe
The female:male susceptibility ratio for SLE is 9–20:1 (69, 80–82). 
Although the precise effect of estrogens in human SLE is not clear, 
unlike MS, a majority of studies have shown that estrogen is not 
protective in SLE. Rather, studies in a number of relevant animal 
models for SLE show that estrogen may have opposite effects. 
Several studies have shown that estrogen enhances severity and 
flares of disease in both human and animal models (83, 84). 
Estrogen enhances anti-double-stranded DNA antibody and 
IgG, IgM production by PBMCs, and serum from patients with 
SLE (85). Estrogen increases reactivity to exogenous antigens 
and also increases expression of endogenous autoantigens, e.g., 
human endogenous retrovirus (HERV) (86, 87), which molecu-
larly mimics RNP antigens, and is increased in SLE patients (88). 
Estrogen also promotes systemic inflammation and induction 
of B cell activating factor and IFN signature genes (89). Over 
50% of the genes that are altered during menstrual cycle are also 
markedly altered in SLE patients when compared to healthy con-
trols (90). Tumor necrosis factor receptor superfamily member 
(TNFRSF14) also called Herpes virus entry mediator (HVEM), 
which interacts with B and T lymphocyte attenuator (BTLA) 
and downregulates lymphocyte activation and homeostasis 
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(91), is altered in normal females when compared to males, as 
well as in SLE patients when compared to normal controls (90). 
Although during a menstrual cycle, there is estrogen-mediated 
increased expression of TNFRSF14 mRNA in PBMCs, in SLE 
patients, there is decreased TNFRSF14 mRNA, which results in 
only partial immune suppression by BTLA culminating in overall 
immune enhancement (91, 92).
Altered ER expression in SLE patients and different murine 
lupus models potentially results in their hyper-reactivity to 
estrogen (93, 94). There is increased ERα and decreased ERβ 
mRNA expression in PBMCs of SLE patients (94). Increased 
ERα expressing CD4+ and CD8+ T cells and ERα+ DCs and 
macrophages in estrogen-treated autoimmune SNF(1) mice as 
compared to control DBF(1) mice has also been reported (95). It 
is evident from different studies that ERα-mediated signaling is 
required for exaggeration of lupus disease (95, 96). Furthermore, 
ERα polymorphism is also reported in SLE patients (97, 98). 
Different risk alleles susceptibility loci, lupus-susceptibility 
genes, and SNPs have also been identified in SLE patients such 
as interferon regulatory factor (IRF5); HLA-DR2 and HLA-DR3, 
Ifi202 of Ifi200-family, PTPN22, CTLA4, STAT4 and BANK1, 
TLR 7, 8, 9, etc. (99–103). Nuclear antigens activate TLR7- and 
TLR9-mediated IRF5 activation, which increases IFNα secre-
tion in SLE patients (104, 105). Estrogen signaling via ERα also 
upregulates IRF5 mRNA (106). Recent reports have implied an 
important role for TLR8 and TLR9 in checking TLR7-mediated 
spontaneous autoimmunity in mice (107). In addition, X-linked 
TLR8 dosage also plays critical role in increased susceptibility of 
females to SLE (108). Single copy of TLR8 in 564Igi Tlr7/9−/− mice 
is not enough for autoantibody production, granulopoeisis, and 
Ifn-I expression (108). Although unclear how estrogen promotes 
lupus in relevant EAE, it is conceivable that estrogen may have 
complex multicellular effects that include altered ER signaling, 
stimulating pro-inflammatory cytokines from Th and other cells, 
augmenting pathogenic autoantibodies by favoring localized 
action of Th2 cells, aberrant TLR-mediated signaling, enhancing 
autoantigen presentation, downregulating regulatory apparatus, 
and dysregulating microRNA expression.
COnCLUSiOn
There is now a wealth of data that affirms estrogen regulates vari-
ous facets of the immune system via complex molecular mecha-
nisms. Although both MS and SLE are autoimmune diseases, 
they differ in many respects that include target pathological 
organs, triggering and pathogenic mechanisms, predominant 
effector cell type(s), genetics, and epigenetics among others. 
Given that estrogen affects all cells of the immune system as well 
as non-lymphoid tissues (e.g., vascular endothelial cells) that 
are in proximity of target tissues, it is conceivable that estrogen 
will have different local effects. Therefore, it is not surprising 
that estrogen has been shown to have different effects in various 
autoimmune diseases. While sex hormones may play a role in 
sex-differences in autoimmune diseases, clearly sex hormones 
alone do not exclusively contribute to this sex differential sus-
ceptibility. Precisely why females are more susceptible to autoim-
mune diseases continues to be an intriguing area of investigation. 
It is therefore important to fully understand the complex inter-
action of estrogen in context-specific situations. It is plausible 
that estrogen may have varied epigenetic effects (microRNAs, 
histone modifications, and/or acetylation) (109) and differ-
ent ER-mediated post-translational modifications in different 
diseases such as in MS and SLE. Indeed, we have shown that 
estrogen induces signature miRNA expression in lymphocytes 
(14) and accelerates the expression of lupus-associated miRNAs 
in lupus-prone mice (110). It is also likely that the microbiome 
in MS and SLE are different. Microbiome can affect sex hormone 
production and vice  versa (111, 112), which in turn affects 
systemic immune responses. Local estrogen and response levels 
altered by microbiome may be different in these two autoimmune 
diseases, an aspect that merits investigations. It is conceivable that 
any immune cell (innate and adaptive) that expresses ERα and/or 
ERβ can potentially respond to estrogen in a context-dependent 
fashion, which will affect the outcome of immune or autoim-
mune responses. Given spatial and temporal expression of ERs, it 
is important to have a comprehensive knowledge and evaluation 
of ER expression in a particular tissue before designing potential 
ER-targeted therapies. In relation to personalized medicine, with 
the advent of highly sensitive molecular arrays, metagenomics 
and bioinformatics, it is plausible to integrate these techniques to 
better predict the estrogen-mediated immunomodulatory effects 
in a disease-specific fashion.
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